ScreenerHero

MDGL Madrigal Pharmaceuticals, Inc. - Common Stock

NAS · US · Healthcare · Biotechnology · madrigalpharma.com
494.38USD-1.01%Mkt Cap: 11.54B $P/E: —

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directe…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap11.54B USD
Enterprise Value11.05B USD
Revenue (TTM)1.28B USD
Gross Profit902.25M USD
Net Income (TTM)-288.28M USD
Revenue/Share56.15 USD
Last Price494.38 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees915
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)51.89
PEG—
EV/EBITDA-34.40
EV/Revenue8.60
P/S8.99
P/B22.02
EPS (TTM)-12.85
EPS (Forward)9.63
52W Range
393.6146% of range615.00
52W High615.00 USD
52W Low393.61 USD
Profitability
Gross Margin94.14%
Oper. Margin-15.46%
EBITDA Margin-25.01%
Profit Margin-30.08%
ROE-47.83%
ROA-22.89%
Growth
Revenue Growth71.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-189.55M USD
CapEx (TTM)3.47M USD
FCF Margin-6.27%
FCF Yield-0.70%
Net Debt-491.00M USD
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity0.58
Current Ratio3.21
Quick Ratio2.75
Book Value/Sh22.68 USD
Cash/Share36.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 25, 2016
Splits
Last Split1:35
Split DateJul 25, 2016
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)682.11 USD
Upside (mean)+38.0%
Target Range543.00 USD – 962.00 USD
543.00+38.0% to mean962.00
# Analysts18
Ownership
Shares Out.23.10M
Float13.72M
Insiders5.83%
Institutions104.63%
Short Interest
Short Ratio10.2d
Short % Float11.47%
Short % Out.9.76%
Shares Short2.25M
Short (prev mo.)2.03M
Technical
SMA 50523.25 (-5.5%)
SMA 200510.61 (-3.2%)
Beta-0.99
S&P 52W Chg14.58%
Avg Vol (30d)235.49K
Avg Vol (10d)244.52K
Technical Indicators
RSI (14)37.9
MACD-6.6558
MACD Signal-3.2410
MACD Hist.-3.4148
BB Upper555.38 USD
BB Middle524.64 USD
BB Lower493.91 USD
BB Width11.72%
ATR (14)16.96 USD
Vol Ratio (20d)1.28x